United States - English - NLM (National Library of Medicine)

b. braun medical inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dopamine hydrochloride 80 mg in 100 ml - dopamine hydrochloride in 5% dextrose injection usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure, and chronic cardiac decompensation as in congestive heart failure. where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine. patients most likely to respond adequately to administration of dopamine are those in whom physiological parameters such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine, the better the prognosis. poor perfusion of vital organs - urine flow appears to be one of the diagnostic signs by which adequacy of vital organ perfusion can be monitored.

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - dopamine hydrochloride - concentrate for soln for inf - 40 mg/ml - adrenergic and dopaminergic agents

United States - English - NLM (National Library of Medicine)

energique, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - may temporarily relieve symptoms associated with reactions to dopamine.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with reactions to dopamine.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride, usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hydrochloride, usp are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride, usp, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride, usp. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be mon

United States - English - NLM (National Library of Medicine)

american regent, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 160 mg in 1 ml

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride in 5% dextrose injection, usp is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. when indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. poor perfusion of vital organs: although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 ml/minute prognosis is more favorable. however, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. the drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. low cardiac output: dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. increased output has been associated with unchanged or decreased systemic vascular resistance (svr). the association of static or decreased svr with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension: low to moderate doses of dopamine, which have little effect on svr, can be used to manage hypotension due to inadequate cardiac output. at high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished svr. as in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. dopamine hydrochloride should not be used in patients with pheochromocytoma. dopamine should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillation. to open tear outer wrap at notch and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. preparation for administration (use aseptic technique) 1. close flow control clamp of administration set. 2. remove cover from outlet port at bottom of container. 3. insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. 4. suspend container from hanger. 5. squeeze and release drip chamber to establish proper fluid level in chamber. 6. open flow control clamp and clear air from set. close clamp. 7. attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. 8. regulate rate of administration with an infusion pump, preferably a volumetric pump. warning: do not use flexible container in series connections.

Malta - English - Medicines Authority

hospira uk limited - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Canada - English - Health Canada

hospira healthcare ulc - dopamine hydrochloride; dextrose - solution - 1.6mg; 50mg - dopamine hydrochloride 1.6mg; dextrose 50mg - selective beta 1-adrenergic agonists

Canada - English - Health Canada

hospira healthcare ulc - dopamine hydrochloride; dextrose - solution - 0.8mg; 50mg - dopamine hydrochloride 0.8mg; dextrose 50mg - selective beta 1-adrenergic agonists

Canada - English - Health Canada

hospira healthcare ulc - dopamine hydrochloride; dextrose - solution - 3.2mg; 50mg - dopamine hydrochloride 3.2mg; dextrose 50mg - selective beta 1-adrenergic agonists